Novo Nordisk launched Awiqli in the U.S. as the first once-weekly basal insulin for adults with type 2 diabetes. The new treatment option aims to improve patient adherence and convenience.
This release follows the company’s first-half 2026 financial report published on August 4. Novo Nordisk also recently filed legal action against a competitor regarding GLP-1 product advertising. The firm continues to expand its market share in the diabetes and obesity sectors.